Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of T-Guard versus ruxolitinib in steroid-refractory acute graft-versus-host disease
NL-OMON50082Phase 3Active, not recruiting
- Sponsor
- Xenikos
- Start
- Sep 2022
- Modality
- Small Molecules, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Acute Graft-Versus-Host Disease (aGvHD) comparing T-Guard with Ruxolitinib (2 arms). Primary endpoint: Complete response rate at Day 28. Started Sep 2022; status: active, not recruiting.
02
Drugs
T-Guardruxolitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON50082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50082.